New Insights on Fak and Fak Inhibitors

被引:15
|
作者
Brullo, Chiara [1 ]
Tasso, Bruno [1 ]
机构
[1] Univ Genoa, Dept Pharm, Viale Benedetto XV 3, I-16132 Genoa, Italy
关键词
Focal adhesion kinase; Fak inhibitors; metastasis; cancer therapy; clinical trials; PROTACS; FOCAL-ADHESION KINASE; NUCLEAR FAK; SELECTIVE INHIBITOR; SIGNAL-TRANSDUCTION; CRYSTAL-STRUCTURE; ENDOTHELIAL FAK; CANCER; PYK2; PATHWAYS; ANTITUMOR;
D O I
10.2174/0929867327666201103162239
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: Focal adhesion kinase (Fak) is a cytoplasmic protein tyrosine ki-nase overexpressed and activated in different solid cancers; it has shown an important role in metastasis formation, cell migration, invasion and angiogenesis and consequently it has been proposed as a potential target in cancer therapy, particularly in a metastatic phase. In recent years, different investigations have highlighted the importance of new Fak inhibitors as potential anti-cancer drugs, but other studies evidenced its role in different pathologies related to the cardiac function or viral infection. Methods: An extensive bibliographic research (104 references) has been done concerning the structure of Fak, its importance in tumor development, but also in other pathologies currently under study. The compounds currently subjected to clinical studies were therefore treated using the appropriate databases. Finally, the main chemical scaffolds currently under preclinical investigation were analyzed, focusing on their molecular structures and on the activity structure relationships (SAR). Results: At the moment, only a few reversible ATP-competitive inhibitors are under investigation in pre-clinical studies and clinical trials. Other compounds, with different chemical scaffolds, are investigated to obtain more active and selective Fak inhibitors. This mini-review is a summary of different Fak functions in cancer and other pathologies; the compounds today in clinical trials and the recent chemical scaffolds (also included in patents) giving the most interesting results are investigated. In addition, PROTAC molecules are reported. Conclusion: All reported results evidenced that additional studies are necessary to design and synthesize new selective and more active compounds, although promising information has been obtained from associations between Fak inhibitors and other different anti-cancer drugs. In addition, the other important roles evidenced, both at the nuclear level and in non-cancerous cells, make this protein an increasingly important target in pharmaceutical chemistry. <comment>Superscript/Subscript Available</comment
引用
收藏
页码:3318 / 3338
页数:21
相关论文
共 50 条
  • [31] Dual roles of FAK in tumor angiogenesis: A review focused on pericyte FAK
    Zhang, Jingyu
    Li, Wei
    Wang, Wenxin
    Chen, Qingqing
    Xu, Zishan
    Deng, Meijing
    Zhou, Lin
    He, Guoyang
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2023, 947
  • [33] Synergism of FAK and ROS1 inhibitors in the treatment of CDH1-deficient cancers mediated by FAK-YAP signaling
    Gao, Jiaming
    Yao, Yunying
    Liu, Chenxuan
    Xie, Xi
    Li, Donghe
    Liu, Ping
    Wang, Zaiqi
    Zhang, Baoyuan
    Ren, Ruibao
    INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2023, 19 (09): : 2711 - 2724
  • [34] Off-targets effects underlie the inhibitory effect of FAK inhibitors on platelet activation: studies using Fak-deficient mice
    Roh, M. E.
    Cosgrove, M.
    Gorski, K.
    Hitchcock, I. S.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 (09) : 1776 - 1778
  • [35] Design, synthesis, and biological evaluation of novel FAK scaffold inhibitors targeting the FAK-VEGFR3 protein-protein interaction
    Gogate, Priyanka N.
    Ethirajan, Manivannan
    Kurenova, Elena V.
    Magis, Andrew T.
    Pandey, Ravindra K.
    Cance, William G.
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2014, 80 : 154 - 166
  • [36] The Role of FAK in Hepatocarcinogenesis
    Shang, Na
    Arteaga, Maribel
    Qiu, Wei
    GASTROENTEROLOGY, 2014, 146 (05) : S999 - S1000
  • [37] Ras and the FAK Paradox
    Antonyak, Marc A.
    Cerione, Richard A.
    MOLECULAR CELL, 2009, 35 (02) : 141 - 142
  • [38] Fak and focal adhesions
    Martin, GM
    JAPANESE JOURNAL OF CANCER RESEARCH, 1996, 87 (03): : COV2 - COV2
  • [39] FAK Signaling in Rhabdomyosarcoma
    Perrone, Clara
    Pomella, Silvia
    Cassandri, Matteo
    Braghini, Maria Rita
    Pezzella, Michele
    Locatelli, Franco
    Rota, Rossella
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (22) : 1 - 19
  • [40] Progress in the Development of Small Molecular Inhibitors of Focal Adhesion Kinase (FAK)
    Lu, Yang
    Sun, Haiying
    JOURNAL OF MEDICINAL CHEMISTRY, 2020, 63 (23) : 14382 - 14403